Dravet syndrome represents a catastrophic, developmental, and epileptic encephalopathy that begins during infancy. Most affected children carry pathogenic mutations in the SCN1A gene, which impairs voltage-gated sodium channel function. Consequently, clinicians face profound challenges when managing these patients because intractable, prolonged convulsive seizures, recurrent status epilepticus, and cognitive decline regularly occur. Standard antiseizure medications often fail to provide adequate disease control. Therefore, evaluating targeted therapies like stiripentol in Dravet syndrome remains vital for optimizing long-term therapeutic strategies. Stiripentol enhances central gamma-aminobutyric acid (GABA) transmission by directly modulating GABA_A receptors. Furthermore, the molecule inhibits cytochrome P450 enzymes, which elevates concomitant plasma concentrations of clobazam and valproate. Although early clinical trials confirmed short-term benefits, clinicians required extensive real-world evidence to confirm sustained durability. A comprehensive 3-year prospective postmarketing surveillance investigation from Japan now offers crucial clarity. This landmark study evaluated 520 patients across a wide age spectrum over 156 weeks. Ultimately, the findings establish clear longitudinal evidence regarding therapeutic effectiveness, adverse event profiles, and general safety. These valuable insights empower neurologists and pediatricians to tailor comprehensive care regimens more effectively.

Evaluating Stiripentol in Dravet Syndrome: Real-World Study Design

Postmarketing surveillance provides indispensable evidence because clinical trials frequently exclude medically complex patients. Consequently, Japanese researchers initiated a nationwide, prospective registry following the commercial authorization of stiripentol. The study enrolled all consecutive patients diagnosed with Dravet syndrome who initiated treatment between November 2012 and August 2017. Investigators maintained observational follow-up for up to 156 weeks to capture long-term therapeutic trajectories. Treating physicians documented detailed clinical parameters, including baseline seizure characteristics, co-administered antiseizure medications, and demographic features. In total, the safety analysis set included 520 patients, whereas the effectiveness analysis set comprised 515 individuals. Notably, the cohort displayed an equal sex distribution, containing 266 males and 254 females. The study population had a mean age of 10 years and 6 months, spanning a diverse range from infants younger than one year up to adults aged 50 years. Physicians recorded adverse drug reactions systematically by grading clinical severity and causal relatedness. Simultaneously, clinicians quantified effectiveness through comprehensive global evaluations and detailed seizure diaries. Therefore, this robust methodology ensured an authentic representation of day-to-day clinical practice across tertiary neurological centers and community pediatric practices.

Key Efficacy Outcomes and Long-Term Seizure Reduction

Achieving meaningful seizure control in severe epileptic encephalopathies requires durable therapeutic performance over multiple years. In this extensive cohort, stiripentol demonstrated notable clinical efficacy across prolonged timelines. Specifically, treating physicians reported an overall clinical improvement rate of 37.7% at week 156 or at treatment discontinuation, defining outcomes as marked or moderate improvement. Furthermore, investigators observed substantial decreases across all individual seizure types, including generalized tonic-clonic, myoclonic, and focal impaired awareness seizures. In addition, the therapy markedly reduced the frequency and severity of episodes of status epilepticus, which represents the most dangerous neurological emergency in Dravet syndrome. Real-world analysis demonstrated that earlier treatment initiation often yielded superior seizure reduction. When clinicians introduced the drug during early childhood, patients frequently experienced pronounced decreases in convulsive episodes. Caregivers recorded these persistent improvements in standardized seizure diaries throughout the entire 3-year surveillance period. Consequently, these robust outcomes confirm that stiripentol maintains its antiepileptic potency without significant pharmacological tolerance developing over prolonged treatment courses. Thus, the drug solidifies its standing as an indispensable component of chronic disease management.

Safety Profile and Management of Adverse Drug Reactions

Long-term pharmacological safety remains a primary consideration when treating chronic pediatric and adult epilepsy. In the safety cohort of 520 patients, adverse drug reactions occurred in 69.2% of individuals over the 3-year surveillance period. Most adverse reactions presented with mild to moderate intensity and emerged primarily during the initial titration phase. Specifically, the most frequent adverse events included somnolence, decreased appetite, dizziness, and subsequent weight loss. Because stiripentol potently inhibits CYP2C19 and CYP3A4 enzymes, it substantially increases active plasma metabolites of co-prescribed medications like clobazam. Therefore, clinicians successfully alleviated severe somnolence and lethargy by adjusting the dosages of companion drugs rather than abandoning therapy altogether. In total, twelve deaths occurred during the prolonged observational timeframe. However, rigorous epidemiological assessment confirmed that this mortality rate did not exceed expected baseline mortality for Dravet syndrome cohorts. Furthermore, the extensive analysis revealed no novel or unexpected safety signals throughout 156 weeks of continuous administration. Consequently, proactive clinical monitoring and gradual dosage adjustments enable healthcare providers to maintain optimal patient safety while preventing avoidable treatment discontinuations.

Clinical Implications for Pediatric and Adult Epilepsy Care

These real-world findings offer vital guidance for pediatricians, pediatric neurologists, and adult epilepsy specialists worldwide. Historically, clinicians possessed limited prospective safety data regarding the use of stiripentol in teenage and adult populations with Dravet syndrome. Fortunately, this nationwide cohort included patients up to 50 years of age, demonstrating that therapeutic utility extends well beyond early childhood. Although convulsive seizures may change in semiology as patients transition into adulthood, severe seizure exacerbations remain common. Therefore, maintaining sustained adjunctive therapy prevents sudden catastrophic status epilepticus and minimizes hospitalization rates. Moreover, managing nutritional intake and body weight represents an essential clinical responsibility. Because anorexia and weight reduction occur frequently, regular dietary assessments and close collaboration with pediatric dietitians optimize patient vitality. Additionally, monitoring baseline liver function and complete blood counts ensures early detection of potential metabolic anomalies. Clinicians should educate caregivers about common side effects and the necessity of maintaining strict treatment adherence. Thus, structured multidimensional management allows medical teams to maximize neurological stability and support better overall quality of life.

Future Directions and Optimizing Multimodal Regimens

Modern epilepsy care increasingly emphasizes personalized polytherapy to tackle complex pharmacological resistance. Stiripentol plays an integral role when combined with first-line sodium valproate and clobazam. However, recent therapeutic advances have introduced novel agents, such as fenfluramine and cannabidiol, into the clinical armamentarium. Consequently, future clinical investigations must examine how stiripentol interacts synergistically with these newer disease-modifying therapies. Clinicians must carefully navigate pharmacokinetic drug-drug interactions when combining multiple hepatic-metabolized molecules. Furthermore, researchers should explore whether early administration prevents the cognitive regression and behavioral comorbidities that characteristically develop in Dravet syndrome. In particular, early seizure cessation may preserve crucial neurodevelopmental trajectories during formative childhood stages. In resource-diverse global settings, including South Asia, improving access to specialized genetic testing and orphan epilepsy medications remains paramount. By combining prompt genetic identification with evidence-based pharmacological regimens, clinicians can alter the natural history of this devastating disorder. Ultimately, real-world prospective registries like this Japanese study reinforce the indispensable role of stiripentol in comprehensive, lifelong epilepsy care.

Frequently Asked Questions

How does stiripentol work in managing Dravet syndrome?

Stiripentol acts through a dual therapeutic mechanism. It directly enhances central GABAergic neurotransmission by modulating GABA_A receptors and increasing brain GABA concentrations. Additionally, stiripentol inhibits hepatic cytochrome P450 enzymes (specifically CYP2C19 and CYP3A4), which significantly raises active plasma levels of companion antiseizure drugs like clobazam and valproate.

What are the most common adverse effects observed during long-term therapy?

The most common adverse drug reactions include somnolence, decreased appetite, dizziness, ataxia, and weight loss. These side effects typically appear during initial dosage titration. Clinicians can effectively manage excessive sedation and anorexia by closely monitoring serum levels and systematically reducing the dosages of concomitant medications, particularly clobazam.

Can adults with Dravet syndrome safely receive stiripentol?

Yes, real-world postmarketing surveillance confirms that stiripentol is both safe and effective for adults with Dravet syndrome. The Japanese cohort evaluated patients up to 50 years of age, demonstrating sustained seizure reduction across age groups. Clinicians must tailor dosages and monitor potential drug interactions throughout adulthood.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. Kitamura Y et al. Safety and effectiveness of stiripentol in patients with Dravet syndrome: A prospective, 3-year, postmarketing surveillance study. Dev Med Child Neurol. 2025 Aug. doi: 10.1111/dmcn.16252. PMID: 39923248.
2. Chiron C, Chemaly N, Chancharme L, Nabbout R. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Dev Med Child Neurol. 2023;65(12):1607-1616.
3. Inoue Y, Ohtsuka Y; STP-1 Study Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90-97.